Clinical Trials Directory

Trials / Completed

CompletedNCT05011539

Thiol-disulfide Homeostasis in Patients With Ovarian Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
115 (actual)
Sponsor
Tepecik Training and Research Hospital · Academic / Other
Sex
Female
Age
Healthy volunteers
Accepted

Summary

Ovarian cancer is the third most common after endometrial and cervical cancer in societies with a high standard of living; It is the second most common type of gynecological cancer after cervical cancer in societies with a low standard of living, and it is also the deadliest among gynecological cancers. Dynamic thiol-disulfide homeostasis is an antioxidant system that minimizes oxidative damage and prevents cell damage. In the presence of oxidative stress, the thiol groups combine to form the disulfide structure, and when the oxidative stress condition is over, they are separated into thiol groups again. This homeostasis is impaired in conditions that cause oxidative processes such as diabetes, cardiovascular diseases, cancers, rheumatoid arthritis, and chronic kidney failure. This can be determined by measuring the total thiol and native thiol levels. Likewise, the level of ischemia modified albumin increases in the case of oxidative stress. There are studies on this homeostasis in the literature on many types of cancer; There are studies on endometrial cancer and cervical cancer, which are gynecological cancers In this study, the usability of these tests together with other diagnostic tests in the diagnosis of ovarian cancer will be evaluated.

Conditions

Timeline

Start date
2021-04-09
Primary completion
2022-04-01
Completion
2022-05-01
First posted
2021-08-18
Last updated
2022-10-20

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05011539. Inclusion in this directory is not an endorsement.

Thiol-disulfide Homeostasis in Patients With Ovarian Cancer (NCT05011539) · Clinical Trials Directory